Clinical Trial of ARQ 761 in Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 761
administered intravenously.
Secondary Objectives:
To determine the pharmacokinetic profile of ARQ 761 To assess the preliminary anti-tumor
activity of aRQ 761
Phase:
Phase 1
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)